RT Journal Article
T1 Influence of the surface properties of nanocapsules on their interaction with intestinal barriers
A1 Santalices Ramos, Irene
A1 Torres, Dolores
A1 Lozano, María Victoria
A1 Arroyo-Jiménez, María del Mar
A1 Alonso Fernández, María José
A1 Santander Ortega, Manuel J.
K1 Poloxamer
K1 Chitosan
K1 Polyarginine
K1 Nanocarrier
K1 Nanocapsule
K1 Colloidal
K1 Stability
K1 Lipolysis
K1 Mucoadhesion
K1 Mucodiffusion,
K1 Oral administration
AB Despite the convenience of the oral route for drug administration, the existence ofdifferent physiological barriers associated with the intestinal tract greatly lowers thebioavailability of many active compounds. We have previously suggested the potentialpolymeric nanocapsules, consisting of an oily core surrounded by a polymer shell, as oraldrug delivery carriers. Here we present a systematic study of the influence of the surfaceproperties of these nanocapsules on their interaction with the intestinal barriers. Twodifferent surfactants, Pluronic®F68 (PF68) and F127 (PF127), and two polymeric shells,chitosan (CS) and polyarginine (PARG) were chosen for the formulation of thenanocapsules. We analyzed nine different combinations of these polymers andsurfactants, and studied the effect of each specific combination on their colloidal stability,enzymatic degradation, and mucoadhesion/mucodiffusion. Our results indicate that both,the polymer shell and the surfactants located at the oil/water interface, influence theinteraction of the nanocapsules with the intestinal barriers. More interestingly, accordingto our observations, the shell components of the nanosystems may have either synergicor disruptive effects on their capacity to overcome the intestinal barriers
PB Elsevier
SN 0939-6411
YR 2018
FD 2018
LK http://hdl.handle.net/10347/32100
UL http://hdl.handle.net/10347/32100
LA eng
NO Irene Santalices, Dolores Torres, Mª Victoria Lozano, Mª Mar Arroyo-Jiménez, María José Alonso, Manuel J. Santander-Ortega, Influence of the surface properties of nanocapsules on their interaction with intestinal barriers, European Journal of Pharmaceutics and Biopharmaceutics, Volume 133, 2018, Pages 203-213
NO The authors acknowledge financial support from the TRANS‐INT EuropeanConsortium −FP7, under grant agreement No. 281035 and the Xunta de Galicia(Competitive Reference Groups  ‐FEDER Funds; Ref 2014/043). Irene Santalicesacknowledges a predoctoral grant from the FPU program (No. FPU13/02015) from theMinistry of Education, Culture and Sports, MECD, Spain. The authors acknowledge Servierfor providing Servier Medical Art (http://smart.servier.com/), being the small intestine,intestinal villi and laboratory material and equipment(https://creativecommons.org/licenses/by/3.0/) modified from the original work and usedfor the creation of the graphical abstract and Figure 1.
DS Minerva
RD 28 abr 2026